Donitriptan (International Nonproprietary Name, INN) (code name F-11356) is a triptan drug which was investigated as an antimigraine agent but ultimately was never marketed.
It acts as a high-affinity (pharmacology), affinity, high-efficacy (pharmacology), efficacy/near-full agonist of the 5-HT1B receptor, 5-HT
1B (pK
i = 9.4–10.1; intrinsic activity, IA = 94%) and 5-HT1D receptor, 5-HT
1D receptors (pK
i = 9.3–10.2; intrinsic activity, IA = 97%), and is among the most potency (pharmacology), potent of the triptan series of drugs.
[Perez M, Fourrier C, Sigogneau I, Pauwels PJ, Palmier C, Valentin JP, John GW, Halazy S (1995) Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: Potent agonists for 5-HT1D receptors. ''Journal of Medicinal Chemistry'' 38:3602–3607.] Donitriptan was being developed in France by bioMérieux-Laboratoires Pierre Fabre, Pierre Fabre and made it to Phases of clinical research, phase II clinical trials in Europe before development was discontinued.
References
5-HT1B agonists
5-HT1D agonists
Antimigraine drugs
Indole ethers at the benzene ring
Aromatic nitriles
Phenylpiperazines
Triptans
Abandoned drugs
{{Analgesic-stub